Albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
A NAD⁺-II class riboswitch, termed mini-NAD⁺-II, was first identified through iterative covariance model (CM) searches against representative bacterial genomes in the Genome Taxonomy Database. Mini-NAD⁺-II riboswitches lack the P1a stem and instead fold into a simple H-type pseudoknot, a compact RNA tertiary structure. The conserved nucleotides essential for tertiary contacts and specific recognition of the NMN moiety are retained, as is an A-rich tract following the P1 stem that likely forms a minor groove triplex. Mini-NAD⁺-II riboswitches lack the P1a stem and instead fold into a simple H-type pseudoknot, a compact RNA tertiary structure. The conserved nucleotides essential for tertiary contacts and specific recognition of the NMN moiety are retained, as is an A-rich tract following the P1 stem that likely forms a minor groove triplex. The potential for base pairing with the adjacent Shine–Dalgarno sequence is also retained, suggesting a conserved mechanism of translational regulation.
Yeast estrogen screen (YES) and Yeast androgen screen (YAS) are in vitro screens that have been developed in order to detect estrogenic and androgenic activities, respectively, of natural and synthetic compounds, mixtures and environmental samples. The test is based on genetically modified yeast cells (Saccharomyces cerevisiae), which contain the gene for the human estrogen or androgen receptor coupled to a reporter gene (e.g. lacZ). Activation of the receptor initiates a cascade of events leading to the expression of the reporter gene product (e.g. β-galactosidase) which converts a substrate (e.g. CPRG) which leads to a measurable color change from yellow to red in the medium. Alternative systems are based on the generation of a luminescence signal. Activating (agonistic) samples can be measured directly; inhibiting (antagonistic) activities are measured as the reduction of color development in the presence of a known activating substance.
There are 20 known isotopes of fermium, with atomic weights of 241 to 260, of which 257Fm is the longest-lived with a half-life of 100.5 days. Other isotopes are considerably shorter: 253Fm has a half-life of 3 days, 252Fm of 25.4 h, 255Fm of 20.1 h, while 251Fm of 5.3 h, 254Fm of 3.2 h, and 256Fm of 2.67 hours. All the remaining ones have half-lives ranging from 30 minutes to less than a millisecond. The neutron capture product of fermium-257, 258Fm, undergoes spontaneous fission with a half-life of just 370(14) microseconds; 259Fm and 260Fm also undergo spontaneous fission (t1/2 = 1.5(3) s and 4 ms respectively). This means that neutron capture does not create nuclides with a mass number greater than 257, unless carried out at extremely high flux, as in a nuclear explosion (or the astrophysical r-process), since no accessible fermium isotopes undergo beta minus decay to the next element, mendelevium. Because of this impediment in forming heavier isotopes, these short-lived isotopes 258–260Fm constitute the "fermium gap." Deliberate attempts at nuclear explosion synthesis, however, also failed to create heavier nuclei, and as a result were deemed not worth continuing.
Scottish chemist Thomas Graham (1805–1869) found experimentally that the rate of effusion of a gas is inversely proportional to the square root of the mass of its particles. In other words, the ratio of the rates of effusion of two gases at the same temperature and pressure is given by the inverse ratio of the square roots of the masses of the gas particles.
=== Beginnings and FA Cup glory === Barnsley were established in 1887 as Barnsley St Peter's by Reverend Tiverton Preedy, and they played in the Sheffield and District League from 1890 and in the Midland League from 1895. In 1897, the club dropped the St Peter's part of its name to become simply Barnsley. They joined the Football League in 1898, and struggled in the Second Division for the first decade, due in part to ongoing financial difficulties. In 1910, the club reached the FA Cup final, where they were defeated by Newcastle United. In 1912, they reached the FA Cup final again, and defeated West Bromwich Albion 1–0 to win the trophy for the first time in their history. When league football restarted after the First World War, the 1919–20 season brought some significant changes to the league. The main difference was that the First Division would now have 22 teams, rather than 20. The bottom team from the previous season was Tottenham Hotspur and they were relegated. The first extra place in the First Division went to Chelsea, who retained their place despite finishing second bottom and therefore in the relegation places. Derby County and Preston North End were promoted from the Second Division which left one place to be filled. Having finished the previous season's Second Division in third place, Barnsley expected to achieve First Division status for the first time, but the Football League instead chose to call a ballot of the clubs. The League voted to promote sixth-placed Arsenal, prioritizing historical standing over sporting merit.
Sources: en.wikipedia.org
==== Molecular toxicology ==== The paradigm of toxicological assessment of benzene is shifting towards the domain of molecular toxicology as it allows understanding of fundamental biological mechanisms in a better way. Glutathione seems to play an important role by protecting against benzene-induced DNA breaks and it is being identified as a new biomarker for exposure and effect. Benzene causes chromosomal aberrations in the peripheral blood leukocytes and bone marrow explaining the higher incidence of leukemia and multiple myeloma caused by chronic exposure. These aberrations can be monitored using fluorescent in situ hybridization (FISH) with DNA probes to assess the effects of benzene along with the hematological tests as markers of hematotoxicity. Benzene metabolism involves enzymes coded for by polymorphic genes. Studies have shown that genotype at these loci may influence susceptibility to the toxic effects of benzene exposure. Individuals carrying variant of NAD(P)H:quinone oxidoreductase 1 (NQO1), microsomal epoxide hydrolase (EPHX) and deletion of the glutathione S-transferase T1 (GSTT1) showed a greater frequency of DNA single-stranded breaks.
Nicotinamide riboside (NR) is now known to be an NAD precursor, involved in the biosynthetic pathways that convert B3 vitamins into NAD. NAD is primarily synthesized in mammals de novo from tryptophan, through the Priess-Handler pathway from nicotinic acid (NA) or via a salvage pathway from nicotinamide (NAM).
== Academic career == He received the Standard Oil Foundation for Excellence in Undergraduate Teaching Award in 1970; the Tanner Award for Excellence in Undergraduate Teaching in 1986; and he was elected by students to membership in the Society of the Golden Fleece in 1989. He collaborated with 55 M.S. and Ph.D. colleagues resulting in over 160 referred publications in journals and edited volumes. Following Hiskey's retirement in 1996, the department created the Richard G. Hiskey Graduate Student Fellowship dedicated to the recruitment and retention of outstanding graduate students. Hiskey received Outstanding Alumnus Awards from Kansas State University in 1973, Wayne State University in 1978, Emporia State University in 1979, and the UNC-CH General Alumni Association Faculty Service Award in 1992. He also was a John Simon Guggenheim Foundation Fellow and a Kenan Research Leave Fellow in 1970–71 at the Max Planck Institute for Cell Chemistry. Hiskey's initial research concerned the development of methods for the production of "mixed sulfides" and the features which stabilized or destabilized these molecules. Mixed disulfides occur in the folding and stabilization of proteins via cystine-cystine interactions. Pursuit of the synthesis of insulin led to the development of methods for the production of mixed disulfides containing two or more cystine residues differently S-protected. The second major phase of Hiskey's research program concerned the role of protein-bound X-Carboxyglutamic (GLA) residues in blood clot formation.
Diagnosis is made on interview and physical examination. More than one finger may be affected at a time. Trigger Finger is most common in the thumb and ring finger. The triggering occurs when making a fist or while gripping an object firmly. Triggering can be more noticeable in the morning, presumably because the enlargement of the tendon is maximum when the finger is not being used. Upon waking, the affected person may have to force the triggered fingers open with their other hand. In some, this can be a daily occurrence.
== Diagnosis == The diagnosis of GPS is often difficult, as numerous other diseases can cause the various manifestations of the condition, and the condition itself is rare. The most accurate means of achieving the diagnosis is testing the affected tissues by means of a biopsy, especially the kidney, as it is the best-studied organ for obtaining a sample for the presence of anti-GBM antibodies. On top of the anti-GBM antibodies implicated in the disease, about one in three of those affected also has cytoplasmic antineutrophilic antibodies in their bloodstream, which often precedes the anti-GBM antibodies by a few months or even years. The later the disease is diagnosed, the worse the outcome is for the affected person. In addition, if there is substantial suspicion of the disease, serologic testing for the ELISA assay is usually done by looking for the alpha3 NC1 domain area of collagen IV to avoid false positives.
Sources: en.wikipedia.org
== Nitrogen-14 == Nitrogen-14 makes up the clear majority of natural nitrogen, about 99.62%, and is responsible for the Earth's stable atmosphere. Nitrogen-14 is one of the very few stable nuclides with both an odd number of protons and of neutrons (seven each) and is the only one to make up a majority of its element. Unpaired protons or neutrons contribute a half-integer nuclear spin, which in this case is a spin 1/2 orbital, giving the nucleus a total magnetic spin of one (as the spins prefer to align). The original source of nitrogen-14 and nitrogen-15 in the Universe is believed to be stellar nucleosynthesis, where they are produced as part of the CNO cycle. Nitrogen-14 is the source of naturally occurring, radioactive, carbon-14. Some kinds of cosmic radiation cause a nuclear reaction with nitrogen-14 in the upper atmosphere of the Earth, creating carbon-14, which decays back to nitrogen-14 with a half-life of 5700 years.
==== Rebif ==== Rebif is a disease-modifying drug (DMD) used to treat multiple sclerosis in cases of clinically isolated syndromes as well as relapsing forms of multiple sclerosis and is similar to the interferon beta protein produced by the human body. It is co-marketed by Merck Serono and Pfizer in the US under an exception to the Orphan Drug Act. It was approved in the European Union in 1998, and in the US in 2002; it has since been approved in more than 90 countries worldwide including Canada and Australia. EMD Serono has had sole rights to Rebif in the US since January 2016. Rebif is administered via subcutaneous injection.
Separation of prescribing and dispensing, also called dispensing separation, is a practice in medicine and pharmacy in which the physician who provides a medical prescription is independent from the pharmacist who provides the prescription drug. In the Western world there are centuries of tradition for separating pharmacists from physicians. In Asian countries, it is traditional for physicians to also provide drugs. In contemporary time researchers and health policy analysts have more deeply considered these traditions and their effects. Advocates for separation and advocates for combining make similar claims for each of their conflicting perspectives, saying that separating or combining reduces conflict of interest in the healthcare industry, unnecessary health care, and lowers costs, while the opposite causes those things. Research in various places reports mixed outcomes in different circumstances.
=== Beginnings of molecular cytogenetics === In the 1980s, advances were made in molecular cytogenetics. While radioisotope-labeled probes had been hybridized with DNA since 1969, movement was now made in using fluorescent-labeled probes. Hybridizing them to chromosomal preparations using existing techniques came to be known as fluorescence in situ hybridization (FISH). This change significantly increased the usage of probing techniques as fluorescent-labeled probes are safer. Further advances in micromanipulation and examination of chromosomes led to the technique of chromosome microdissection whereby aberrations in chromosomal structure could be isolated, cloned, and studied in ever greater detail.
Conolidine is an indole alkaloid. Preliminary reports suggest that it could provide analgesic effects with few of the detrimental side-effects associated with opioid. Conolidine was first isolated in 2004 from the bark of the Tabernaemontana divaricata (crape jasmine) shrub which is used in traditional Chinese medicine. The first asymmetric total synthesis of conolidine was developed by Micalizio and coworkers in 2011. This synthetic route allows access to either enantiomer (mirror image) of conolidine via an early enzymatic resolution. Notably, evaluation of the synthetic material resulted in the discovery that both enantiomers of the synthetic compound show analgesic effects.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。